share_log

Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target

Benzinga ·  Apr 29 08:05

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $14 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment